TFF Pharmaceuticals Overview
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert any drug, including vaccines, small and large molecules and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally.
In 2021, TFF Pharmaceuticals hosted two conversations with Key Opinion Leaders to discuss its programs and potential of the Thin Film Freezing technology platform:
- Learn more about TFF’s Inhaled Voriconazole Powder to treat invasive pulmonary aspergillosis at the link here.
- Learn more about TFF’s Inhaled Tacrolimus Powder to prevent immunosuppression from lung transplant as well as applications of Thin Film Freezing technology for vaccine applications in the webcast and presentation here.